Edition:
United Kingdom

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

86.28USD
20 Jun 2018
Change (% chg)

$-0.54 (-0.62%)
Prev Close
$86.82
Open
$86.65
Day's High
$87.16
Day's Low
$86.21
Volume
1,185,924
Avg. Vol
1,237,799
52-wk High
$89.07
52-wk Low
$73.70

Latest Key Developments (Source: Significant Developments)

Eli Lilly's Unit, Bluegill Acquisition Offering To Buy All Of Armo Biosciences's Outstanding Shares For $50/Share
Wednesday, 23 May 2018 

May 23 (Reuters) - ARMO Biosciences Inc ::ARMO BIOSCIENCES - ELI LILLY'S UNIT, BLUEGILL ACQUISITION CORP, OFFERING TO BUY ALL OF CO'S OUTSTANDING SHARES FOR $50/SHARE - SEC FILING.ARMO BIOSCIENCES - ON APRIL 13, LILLY HAD DELIVERED PRELIMINARY INDICATION OF INTEREST REGARDING ACQUISITION OF CO FOR $55/SHARE.  Full Article

EFSD, JDRF And Lilly Extend Collaboration Supporting Type 1 Diabetes Research
Thursday, 8 Mar 2018 

March 8 (Reuters) - Eli Lilly And Co ::EFSD, JDRF AND LILLY EXTEND COLLABORATION SUPPORTING TYPE 1 DIABETES RESEARCH.ELI LILLY AND CO - EFSD, JDRF AND CO AGREED TO EXTEND COLLABORATION FOR EUROPEAN PROGRAMME IN TYPE 1 DIABETES RESEARCH THROUGH 2020​.  Full Article

Boehringer Ingelheim And Lilly Expand Heart Failure Program For Jardiance
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Eli Lilly And Co ::BOEHRINGER INGELHEIM AND LILLY EXPAND HEART FAILURE PROGRAM FOR JARDIANCE® WITH NEW EXERCISE CAPACITY TRIALS.ELI LILLY AND CO - ‍EMPERIAL TRIALS TO EVALUATE EFFECT OF JARDIANCE ON EXERCISE ABILITY, HEART FAILURE SYMPTOMS IN PEOPLE WITH CHRONIC HEART FAILURE​.  Full Article

Lilly Receives Additional FDA Approval For Verzeniotm, As Initial Treatment For Advanced Breast Cancer
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Eli Lilly And Co ::LILLY RECEIVES ADDITIONAL FDA APPROVAL FOR VERZENIOTM (ABEMACICLIB), AS INITIAL TREATMENT FOR ADVANCED BREAST CANCER.ELI LILLY AND CO - ‍NEW INDICATION BASED ON MONARCH 3 TRIAL CAN HELP MORE WOMEN LIVING WITH HR+, HER2- ADVANCED BREAST CANCER​.ELI LILLY - ‍RECOMMENDED DOSE OF VERZENIO IN COMBINATION WITH AI IS 150 MG ORALLY TWICE DAILY, CONTINUED UNTIL DISEASE PROGRESSION/ UNACCEPTABLE TOXICITY​.ELI LILLY AND CO - ‍VERZENIO IS AVAILABLE IN 4 TABLET STRENGTHS (200 MG, 150 MG, 100 MG, AND 50 MG)​.  Full Article

Lilly Receives Additional FDA Approval For Verzenio​
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Eli Lilly And Co ::LILLY RECEIVES ADDITIONAL FDA APPROVAL FOR VERZENIO (ABEMACICLIB), AS INITIAL TREATMENT FOR ADVANCED BREAST CANCER .SAYS ‍NEW INDICATION BASED ON MONARCH 3 TRIAL CAN HELP MORE WOMEN LIVING WITH HR+, HER2- ADVANCED BREAST CANCER​.SAYS ‍RECOMMENDED DOSE OF VERZENIO IN COMBINATION WITH AI IS 150 MG ORALLY TWICE DAILY, CONTINUED UNTIL DISEASE PROGRESSION/ UNACCEPTABLE TOXICITY​.SAYS ‍VERZENIO IS AVAILABLE IN 4 TABLET STRENGTHS (200 MG, 150 MG, 100 MG, AND 50 MG)​.  Full Article

Adocia Files Additional Arbitration Claims Against Eli Lilly & Company​
Tuesday, 6 Feb 2018 

Feb 6 (Reuters) - ADOCIA SA ::‍ADOCIA FILES ADDITIONAL ARBITRATION CLAIMS AGAINST ELI LILLY & COMPANY <<>>​.‍SEEKS DAMAGES OF USD 200 MILLION AND OTHER RELIEF ON CONFIDENTIAL INFORMATION ABUSE AND AGREEMENT BREACHES.EXPECT A DECISION ON THIS CLAIM IN Q2 OF 2018.‍WILL PROVIDE NO ADDITIONAL COMMENT ON THE PROCEEDINGS UNTIL THEIR CONCLUSION​.  Full Article

Elanco Announces Global In-Licensing Agreement With Ab E Discovery
Thursday, 25 Jan 2018 

Jan 25 (Reuters) - Elanco Animal Health::ELANCO ANNOUNCES GLOBAL AGREEMENT WITH AB E DISCOVERY FOR NEW TECHNOLOGY.ELANCO ANIMAL HEALTH SAYS ANNOUNCES A GLOBAL IN-LICENSING AGREEMENT WITH AB E DISCOVERY​.ELANCO ANIMAL HEALTH SAYS IN-LICENSING AGREEMENT TO FURTHER DEVELOP AND BRING TO MARKET AN EGG ANTIBODY FOCUSED ON SUPPORTING GUT HEALTH OF POULTRY​.  Full Article

Lartruvo (Olaratumab) Approved In Canada For The Treatment Of Advanced Soft Tissue Sarcoma In Adults
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Eli Lilly And Co ::LARTRUVO(OLARATUMAB) APPROVED IN CANADA FOR THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA IN ADULTS.ELI LILLY CANADA INC - HEALTH CANADA HAS ISSUED NOTICE OF COMPLIANCE WITH CONDITIONS FOR LARTRUVO.ELI LILLY CANADA - CONFIRMATORY PHASE 3 TRIAL IS CURRENTLY UNDERWAY TO FURTHER VERIFY CLINICAL BENEFIT OF OLARATUMAB.  Full Article

NSAV Subsidiary Signs Agreement With Eli Lilly
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Net Savings Link NSAV.PK::NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY.NET SAVINGS LINK SAYS VSRI WILL PROVIDE ELI LILLY WITH ASSESSMENT OF CVD AMONG NEWLY DIAGNOSED DIABETES PATIENTS AT INCREASED RISK OF CVD IN CHINA.  Full Article

Lilly Announces 2018 Financial Guidance, Enhances Outlook Through 2020
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Eli Lilly And Co ::LILLY ANNOUNCES 2018 FINANCIAL GUIDANCE AND ENHANCES OUTLOOK THROUGH 2020.SEES FY 2018 REVENUE $23 BILLION TO $23.5 BILLION.SEES FY 2017 EARNINGS PER SHARE $1.56 TO $1.66.SEES FY 2018 EARNINGS PER SHARE $4.24 TO $4.34.- REAFFIRMED ITS EXPECTATION OF AT LEAST 5 PERCENT AVERAGE ANNUAL REVENUE GROWTH FROM 2015 TO 2020, ON A CONSTANT CURRENCY BASIS.FY2017 EARNINGS PER SHARE VIEW $4.21 -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $4.64, REVENUE VIEW $23.07 BILLION -- THOMSON REUTERS I/B/E/S.ELI LILLY - EXPECT OPERATING MARGIN AS PERCENT OF REVENUE TO BE AT LEAST 30 PERCENT IN 2020, EXCLUDING EFFECT OF FOREX ON INTERNATIONAL INVENTORIES SOLD.- ON A NON-GAAP BASIS, REAFFIRMED 2017 EPS TO BE IN RANGE OF $4.15 TO $4.25.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $4.60 TO $4.70.- SEES 2018 CAPITAL EXPENDITURES ABOUT $1.2 BILLION.ELI LILLY SEES 2018 REVENUE GROWTH DRIVEN BY NEW PRODUCTS INCLUDING TRULICITY, BASAGLAR, JARDIANCE, VERZENIO, OLUMIANT.ELI LILLY - REVISION TO 2017 EARNINGS PER SHARE OUTLOOK IS DUE TO CHANGES IN ESTIMATES RELATED TO ASSET IMPAIRMENT, RESTRUCTURING, OTHER SPECIAL CHARGES.  Full Article

UPDATE 1-Lilly's lupus treatment succeeds in mid-stage trial

June 13 Eli Lilly & Co said on Wednesday its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year.